Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: A prospective cohort study

Leukemia and Lymphoma

Volumn 53, Issue 1, 2012, Pages 57-63

  Minuk, Leonard A ^a   Monkman, Katherine ^a   Chin Yee, Ian H ^a   Lazo Langner, Alejandro ^a   Bhagirath, Vinai ^a   Chin Yee, Benjamin H ^a   Mangel, Joy E ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Chemotherapeutic approaches; Infectious complications; Lymphoma and Hodgkin disease

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; FEBRILE NEUTROPENIA; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUTROPHIL COUNT; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COST-BENEFIT ANALYSIS; DACARBAZINE; DOXORUBICIN; FEMALE; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 84855464199     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.602771     Document Type: Article

References (28)

1. Landgren O, Caporaso NE. New aspects in descriptive, etiologic, and molecular epidemiology of Hodgkin ' s lymphoma. Hematol Oncol Clin North Am 2007;21:825-840. (Pubitemid 47496094)
2. S traus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:3483-3489. (Pubitemid 39564416)
3. Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin ' s lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 2009;27:5390-5396.
4. Rueda Dominguez A, Marquez A, Guma J, et al. Treatment of stage I and II Hodgkin ' s lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004;15:1798-1804. (Pubitemid 40012246)
5. Silvestri F, Fanin R, Velisig M, et al. Th e role of granulocyte colonystimulating factor (fi lgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin ' s disease. Tumori 1994;80:453-458.
6. Bezwoda WR, Dansey R, Bezwoda MA. Treatment of Hodgkin ' s disease with MOPP chemotherapy: eff ect of dose and schedule modifi cation on treatment outcome. Oncology 1990;47:29-36. (Pubitemid 20027735)
7. van Rijswijk RE, Haanen C, Dekker AW. Dose intensity of MOPP chemotherapy and survival in Hodgkin ' s disease. J Clin Oncol 1989;7:1776-1782. (Pubitemid 20014323)
8. L andgren O, Algernon C, Axdorph U, et al. Hodgkin 's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 2003;88:438-444. (Pubitemid 36547130)
9. Matthews JH. Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin ' s disease: possible synergy. Lancet 1993; 342:988. (Pubitemid 23305513)
10. M artin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin ' s lymphoma. J Clin Oncol 2005;23:7614-7620. (Pubitemid 46291825)
11. B oleti E, Mead GM. ABVD for Hodgkin' s lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 2007;18:376-380. (Pubitemid 46323108)
12. E vens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007;137:545-552. (Pubitemid 46817335)
13. N angalia J, Smith H, Wimperis JZ. Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support. Leuk Lymphoma 2008;49:1530-1536.
14. L ister TA, Crowther D, Sutcliff e SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin ' s disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-1636.
15. H asenclever D, Diehl V. A prognostic score for advanced Hodgkin' s disease. International Prognostic Factors Project on Advanced Hodgkin ' s Disease. N Engl J Med 1998;339:1506-1514. (Pubitemid 28543499)
16. C heson BD, Horning SJ, Coiffi er B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin ' s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
17. D ean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. Updated 2010/19/09. Available from: www.OpenEpi.com
18. K uderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-2266. (Pubitemid 43673249)
19. C aggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916-1924. (Pubitemid 40563265)
20. S mith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24: 3187-3205. (Pubitemid 46638957)
21. S ung L, Nathan PC, Alibhai SM, et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007;147: 400-411. (Pubitemid 351664541)
22. Bohlius J, Herbst C, Reiser M, et al. Granulopoiesis-stimulating factors to prevent adverse eff ects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008;(4):CD003189.
23. D unlop DJ, Eatock MM, Paul J, et al. Randomized multicentre trial of fi lgrastim as an adjunct to combination chemotherapy for Hodgkin ' s disease. West of Scotland Lymphoma Group. Clin Oncol (R Coll Radiol) 1998;10:107-114. (Pubitemid 28209751)
24. R ueda A, Sevilla I, Guma J, et al. Secondary prophylactic G-CSF (fi lgrastim) administration in chemotherapy of stage I and II Hodgkin ' s lymphoma with ABVD. Leuk Lymphoma 2001;41:353-358. (Pubitemid 32499418)
25. Younes A, Fayad L, Romaguera J, et al. Safety and effi cacy of onceper- cycle pegfi lgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 2006;42:2976-2981. (Pubitemid 44667479)
26. Azoulay E, Herigault S, Levame M, et al. Eff ect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fi brosis. Crit Care Med 2003;31:1442-1448. (Pubitemid 36583857)
27. Adamson IY, Bowden DH. Th e pathogenesis of bleomycininduced pulmonary fi brosis in mice. Am J Pathol 1974;77:185-197.
28. Adachi K, Suzuki M, Sugimoto T, et al. Eff ects of granulocyte colony-stimulating factor (G-CSF) on bleomycin-induced lung injury of varying severity. Toxicol Pathol 2003;31:665-673. (Pubitemid 37433477)